Because KLK6 levels are reduced in patients with synucleinopathies including PD (Pampalakis et al., 2017), restoring KLK6 levels may represent a possible therapeutic intervention for these neurodegenerative diseases. This evidence concerns the gene KLK6 and Parkinson disease.